Numer badania Tytuł badania Nowotwór Kategoria chorych Faza badania Sponsor badania Data rozpoczęcia Data zakończenia Ośrodki badawcze Sponsor badania Linki
NCT01395017 Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer rak trzustki II Otsuka 2011-05-31 2014-07-31
Lublin; Olsztyn
 Otsuka
  1. www.clinicaltrials.gov
NCT00634049 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare... przecigrzybicze leczenie III Astellas 2008-03-31 2012-06-30
Warszawa
 Astellas
  1. www.clinicaltrials.gov
NCT01285609 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing... rak płuca 1. linia III BMS 2011-05-31 2016-05-31
Elbląg; Gdańsk; Olsztyn; Szczecin
 BMS
  1. www.clinicaltrials.gov
NCT00209209 Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus... chłoniak płaszcza 1. linia leczenia III University of Cologne 2003-12-31 2013-12-31
CO-I Warszawa Jan Walewski; Ph: +48-22-546-2223; walewski@coi.waw.pl
 University of Cologne
  1. www.clinicaltrials.gov
NCT01098266 NGR015: Study in Second Line for Patient With Advanced Malignant... międzybłoniak opłucnej 1sza linia leczenia III MolMed 2010-02-28 2013-01-31
UCK Gdańsk - Jacek Jassem;
CO-I Warszawa - Paweł Badurak
 MolMed
  1. www.clinicaltrials.gov
NCT00646854 Alemtuzumab and CHOP in T-cell Lymphoma chłoniak T-kom 1sza linia leczenia III Aarhus Universitetshospital 2008-05-31 2016-11-30
CO-I Warszawa; prof.J.Walewski, walewski@coi.waw.pl
 Aarhus Universitetshospital
  1. www.clinicaltrials.gov
NCT00209222 Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)... chłoniak płaszcza 1sza linia leczenia III University of Cologne 2004-06-30 2010-05-31
Jan Walewski;
Ph: +48-22-546-2223;
University of Cologne
  1. www.clinicaltrials.gov
NCT01185847 A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy... rak płuca ALK+ II Roche 2010-10-31 2013-11-30
Łódź; Otwock
 Roche
  1. www.clinicaltrials.gov
NCT00937183 Phase I/II Study of Adjuvant Dendritic Cell-Lymphoma Cell Hybrids and/or... chłoniak B-komórkowy bez progresji II CO-I Warszawa 2003-08-31 2010-05-31
CO-I Warszawa, Jan Walewski, MD Ph: 48-22-546-2223 walewski@coi.waw.pl
 CO-I Warszawa
  1. www.clinicaltrials.gov
NCT00822614 Safety of Fentanyl TAIFUN Treatment choroba nowotworowa ból przebijający III Akela Pharma 2008-11-30 2009-12-31
Zbigniew Kaczmarek - Włocławek
 Akela Pharma
  1. www.clinicaltrials.gov